- Hikma Pharmaceuticals launched Monday its treatment for seizures in patients suffering from Lennox-Gastaut syndrome.

Clobazam Oral Suspension, and Clobazam Tablet, the generic equivalent to Onfi, would be among the first generics available on the market, the company said.

According to IQVIA, US sales of Clobazam Oral Suspension were approximately $260m and of Clobazam Tablets were approximately $601m in the 12 months ending September 2018.

'We are very excited to add Clobazam Oral Suspension and Clobazam Tablets to our product portfolio. This will be among the first generics available on the market and we are pleased to improve patients' access to this important medicine.'

At 10:24am: [LON:HIK] Hikma Pharmaceuticals PLC share price was -16.25p at 1688.25p

Story provided by